Eris Lifesciences Ltd.

ERIS

Market Cap
₹11,840 Cr.
P/E
30.64

Eris Lifesciences Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
Company has made significant capex which might be affecting its ROCE
Depreciation Effect
Company is depreciating a greater percentage of assets. This is contributing to a reduction in Net Profit
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been buying the stock which is usually a sign of exuberance
Share price
Share price has increased over last 10 years but more due to rerating
ROE
ROE has decreased vs 10 year trend
Working Capital
Working Capital of the company seems to be under control
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a discount to 3 year historic valuations
ROE
Latest
17.4%
3yr Average
20.4%
5yr Average
21.87%
Net Profit Margin
Latest
22.68%
3yr Average
27.38%
5yr Average
27.87%
ROCE
Latest
14.61%
3yr Average
22.01%
5yr Average
24.86%
Debt to Equity
Latest
0.38
3yr Average
0.13
5yr Average
0.11
Market Share
3.77% (as of Jul 22)
Anti - Diabetes - Market Share
0.03% (as of Jul 22)
Anti-Infectives - Market Share
0.10% (as of Nov 21)
Blood Related - Market Share
1.99% (as of Jul 22)
Cardiovascular - Market Share
10% (as of Mar 23)
Cyblex - Market Share
locked Source
0.04% (as of Nov 21)
Dermatology - Market Share
9.10% (as of Mar 19)
Desval - Market Share
locked Source
0.10% (as of Nov 21)
Endocrinology - Market Share
4% (as of Mar 23)
Eritel - Market Share
locked Source
0.35% (as of Jul 22)
Gastro-Intestinal - Market Share
38% (as of Mar 23)
Ginkocer - Market Share
locked Source
6% (as of Mar 23)
Glimisave - Market Share
locked Source
0.70% (as of Nov 21)
Gynecology - Market Share
1.20% (as of Mar 19)
Levroxa - Market Share
locked Source
10% (as of Mar 23)
Lnbloc - Market Share
locked Source
8% (as of Sep 22)
Metital - Market Share
locked Source
1.16% (as of Nov 21)
Neurological - Market Share
8% (as of Mar 23)
Olmin - Market Share
locked Source
0.08% (as of Nov 21)
Ophthalmology - Market Share
0.42% (as of Nov 21)
Pain - Market Share
7.30% (as of Dec 22)
Pharmaceutical Sector - Market Share
3% (as of Mar 23)
Rabonik - Market Share
locked Source
10% (as of Mar 23)
Raricap - Market Share
locked Source
4% (as of Mar 23)
Remylin - Market Share
locked Source
8% (as of Mar 23)
Renerve - Market Share
locked Source
0.12% (as of Nov 21)
Respiratory - Market Share
4.50% (as of Mar 19)
Selzic - Market Share
locked Source
16% (as of Mar 23)
Serlift - Market Share
locked Source
3% (as of Mar 23)
Tayo - Market Share
locked Source
8% (as of Mar 23)
Tendia - Market Share
locked Source
2.09% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Entity Wise Breakup

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Acute vs Chronic

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Eris Lifesciences Ltd.
    View the discussion on ValuePickr
    Eris Lifesciences - The Pharma Brand Master - Motilal Oswal
    Eris Lifesciences - how valuable is it? - ValuePickr
    Execution History of Eris Lifesciences - Harsh Beria
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline